Revenue has effectively evaporated with a 100% year-over-year decline in 2026Q2, while operating losses reached $13.3 million, highlighting a cost structure disconnected from commercial output.
| Metric | TTM | Jun'25 | Jun'24 | Jun'23 | Jun'22 | Jun'21 | Jun'20 | Jun'19 | Jun'18 | Jun'17 | Jun'16 | Jun'15 | Jun'14 | Jun'13 | Jun'12 | Jun'11 | Jun'10 | Jun'09 | Jun'08 | Jun'07 | Jun'06 | Jun'05 | Jun'04 | Jun'03 | Jun'02 | Jun'01 | Jun'00 | Jun'99 |
|---|
| Sales/Revenue | 2.52M | 42K | 2.31M | 555 | 10K | 15.18M | 988.11K | 1.56K | 13.11K | 8.79M | 4.07M | 89K | 87K | 1.07M | 2.45M | 2.02M | 9.91M | 11.15M | 13.28M | 17.31M | 13.5M | 17.61M | 16.35M | 32.93M | 19.59M | 58.91M | 26.75M | 19.32M |
| Revenue Growth % | 250944.28% | -98.18% | 415755.86% | -94.45% | -99.93% | 1436.57% | 63038.02% | -88.06% | -99.85% | 115.87% | 4474.16% | 2.3% | -91.85% | -56.44% | 20.99% | -79.56% | -11.12% | -16.03% | -23.33% | 28.21% | -23.3% | 7.71% | -50.36% | 68.06% | -66.74% | 120.27% | 38.41% | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -44.68K | 0 | 0 | 2.22M | 2.52M | 4.09M | 6.95M | 5.45M | 4.65M | 4.72M | 7.17M | 7.59M | 100.82M | 7.11M | 31.76M |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.19% | - | - | 22.37% | 22.63% | 30.79% | 40.16% | 40.34% | 26.39% | 28.9% | 21.78% | 38.73% | 171.14% | 26.58% | 164.34% |
| Gross Profit | 2.52M | 42K | 2.31M | 555 | 10K | 15.18M | 988.11K | 1.56K | 13.11K | 8.79M | 4.07M | 89K | 87K | 1.11M | 2.45M | 2.02M | 7.69M | 8.62M | 9.19M | 10.36M | 8.06M | 12.96M | 11.62M | 25.76M | 12.01M | -41.91M | 19.64M | -12.43M |
| Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 104.19% | 100% | 100% | 77.63% | 77.37% | 69.21% | 59.84% | 59.66% | 73.61% | 71.1% | 78.22% | 61.27% | -71.14% | 73.42% | -64.34% |
| Gross Profit Growth % | - | -98.18% | 415755.86% | -94.45% | -99.93% | 1436.57% | 63038.02% | -88.06% | -99.85% | 115.87% | 4474.16% | 2.3% | -92.18% | -54.61% | 20.99% | -73.67% | -10.81% | -6.13% | -11.33% | 28.59% | -37.83% | 11.52% | -54.88% | 114.53% | 128.65% | -313.43% | 257.93% | - |
| Operating Expenses | 51.21M | 14.26M | 30.77M | 24.12M | 25.41M | 21.56M | 13.18M | 10.25M | 14.69M | 19.66M | 15.64M | 9.68M | 6.74M | 3.11M | 11.19M | 13.46M | 22.92M | 32.4M | 35.02M | 37.38M | 30.36M | 25.13M | 24.01M | 36.26M | 31.01M | 0 | 33.29M | 5.69M |
| OpEx % of Revenue | - | 33950% | 1333.19% | 4346761.08% | 254090% | 141.99% | 1334.28% | 655143.77% | 112046.08% | 223.67% | 384.11% | 10876.67% | 7750.54% | 291.09% | 456.82% | 664.89% | 231.33% | 290.65% | 263.77% | 215.88% | 224.83% | 142.75% | 146.87% | 110.11% | 158.24% | 0% | 124.47% | 29.46% |
| Selling, General & Admin | 26.02M | 8.72M | 13.56M | 8.58M | 5.24M | 7.02M | 3.69M | 3.79M | 5.6M | 8.53M | 5.76M | 3.84M | 4.27M | 2.85M | 5.79M | 9.56M | 14.83M | 13.24M | 16.22M | 21.23M | 18.34M | 14.96M | 15.79M | 28.03M | 23.15M | 0 | 26.97M | 749.01K |
| SG&A % of Revenue | - | 20761.9% | 587.65% | 1546488.65% | 52400% | 46.24% | 373.43% | 241916.93% | 42706.74% | 97.05% | 141.51% | 4318.86% | 4904.76% | 267.06% | 236.29% | 472.2% | 149.65% | 118.8% | 122.16% | 122.59% | 135.83% | 84.95% | 96.63% | 85.14% | 118.14% | - | 100.83% | 3.88% |
| Research & Development | 25.19M | 7.33M | 17.38M | 15.56M | 20.17M | 14.54M | 9.49M | 6.48M | 9.77M | 11.14M | 9.89M | 5.94M | 2.48M | 256.41K | 5.4M | 3.9M | 8.09M | 18.79M | 18.8M | 16.15M | 12.02M | 10.18M | 8.21M | 8.22M | 7.86M | 0 | 5.93M | 3.6M |
| R&D % of Revenue | - | 17442.86% | 753.03% | 2804336.94% | 201690% | 95.77% | 960.86% | 413801.92% | 74565.15% | 126.72% | 243.04% | 6668.94% | 2845.78% | 24.02% | 220.53% | 192.69% | 81.68% | 168.55% | 141.62% | 93.29% | 88.99% | 57.8% | 50.24% | 24.97% | 40.11% | - | 22.16% | 18.6% |
| Other Operating Expenses | 0 | -1.79M | -173K | -22.56K | 0 | -2K | 0 | -9K | 3.67M | 0 | 0 | 1.54M | 0 | 6.03K | 0 | 0 | 0 | 27K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27.37M | 2.1M |
| Operating Income | -47.1M | -14.22M | -28.46M | -24.12M | -25.4M | -6.38M | -12.2M | -8.38M | -12.49M | -10.85M | -12.77M | -8.14M | -6.4M | -2.04M | -9.68M | -11.44M | -15.23M | -23.77M | -25.83M | -27.02M | -22.3M | -12.17M | -12.39M | -10.5M | -19M | -41.91M | -13.66M | -18.13M |
| Operating Margin % | -1866.72% | -33850% | -1233.19% | -4346661.08% | -253990% | -41.99% | -1234.28% | -535463.26% | -95262.44% | -123.49% | -313.71% | -9147.19% | -7357.47% | -191.04% | -395.06% | -564.89% | -153.69% | -213.29% | -194.57% | -156.04% | -165.16% | -69.14% | -75.77% | -31.89% | -96.97% | -71.14% | -51.06% | -93.8% |
| Operating Income Growth % | - | 50.05% | -17.98% | 5.02% | -298.35% | 47.72% | -45.54% | 32.89% | -15.06% | 15.02% | -56.87% | -27.18% | -213.93% | 78.93% | 15.39% | 24.88% | 35.95% | 7.95% | 4.39% | -21.12% | -83.23% | 1.71% | -17.95% | 44.74% | 54.67% | -206.91% | 24.66% | - |
| EBITDA | -45.23M | -13.28M | -26.59M | -22.25M | -23.53M | -5.11M | -11.11M | -7.3M | -10.94M | -9.44M | -12.13M | -7.57M | -5.83M | -1.7M | -9.65M | -11.36M | -15.03M | -23.49M | -25.48M | -26.04M | -20.92M | -10.55M | -10.67M | -8.62M | -17.15M | -41.23M | -13.66M | -16.78M |
| EBITDA Margin % | -1792.64% | -31626.19% | -1152.21% | -4009821.44% | -235300% | -33.66% | -1124.54% | -466198.08% | -83475.74% | -107.4% | -297.92% | -8501.16% | -6699.84% | -159.54% | -394.04% | -560.79% | -151.7% | -210.76% | -191.91% | -150.4% | -154.87% | -59.94% | -65.3% | -26.17% | -87.51% | -69.99% | -51.06% | -86.82% |
| EBITDA Growth % | 17.28% | 50.05% | -19.49% | 5.42% | -360.38% | 54% | -52.3% | 33.32% | -15.93% | 22.18% | -60.3% | -29.8% | -242.31% | 82.36% | 14.99% | 24.44% | 36.02% | 7.78% | 2.16% | -24.5% | -98.18% | 1.13% | -23.86% | 49.73% | 58.42% | -201.95% | 18.61% | - |
| D&A (Non-Cash Add-back) | 1.87M | 934K | 1.87M | 1.87M | 1.87M | 1.26M | 1.08M | 1.08M | 1.54M | 1.41M | 642.64K | 574.96K | 572.14K | 336.18K | 25K | 83K | 198K | 282K | 353.28K | 976.21K | 1.39M | 1.62M | 1.71M | 1.88M | 1.85M | 678.03K | 0 | 1.35M |
| EBIT | -47.1M | -14.22M | -28.46M | -24.15M | -25.38M | -6.38M | -12.19M | -8.79M | -14.57M | -10.85M | -12.36M | -8.05M | -6.31M | -1.38M | -1.47M | -5.32M | -15.8M | -23.77M | -25.83M | -27.02M | -18.36M | -12.86M | -12.39M | -10.5M | -19M | -41.91M | -13.66M | -18.13M |
| Net Interest Income | 219.93K | 72K | 12K | 22.84K | 2K | 42.24K | 66K | -2.09M | 0 | 0 | 0 | 20.64K | -627.84K | -87K | 248K | 126K | -15K | -11K | -24.04K | -2.36K | 1.41M | 1.26M | 1.11M | 0 | -344.58K | 0 | 0 | 0 |
| Interest Income | 219.93K | 72K | 12K | 22.84K | 2.09K | 42.24K | 66K | 100K | 119K | 276 | 406K | 89.26K | 86.69K | 44.62K | 248K | 144K | 0 | 0 | -1 | 0 | 1.46M | 1.31M | 1.22M | 0 | -1 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 2.09K | 0 | 0 | 2.19M | 0 | 0 | 0 | 68.62K | 714.52K | 131.7K | 0 | 18K | 15K | 11K | 24.04K | 2.36K | 52.56K | 56.39K | 118.72K | 0 | 344.58K | 0 | 0 | 0 |
| Other Income/Expense | -5.76M | -8.23M | 1.41M | 3.41M | 17K | -2.53M | -569.58K | -1.75M | 6.02M | 7.87K | 227.97K | 754.79K | -1.25M | 531K | 937K | 6.1M | -15K | -11K | 1.07M | 2.69M | 444.71K | 633.44K | 0 | 78.66K | 4.38M | -679.99K | 0 | 599.21K |
| Pretax Income | -52.86M | -22.45M | -27.05M | -20.74M | -25.38M | -8.9M | -12.77M | -10.57M | -6.34M | -10.87M | -12.15M | -7.31M | -7.57M | -1.51M | -8.74M | -10.95M | -15.24M | -23.79M | -24.76M | -24.32M | -17.92M | -12.23M | 0 | -10.42M | -14.62M | -42.59M | -13.66M | -17.53M |
| Pretax Margin % | -2095.13% | -53447.62% | -1171.97% | -3736265.23% | -253820% | -58.64% | -1291.93% | -675271.57% | -48397.92% | -123.68% | -298.58% | -8209.04% | -8699.68% | -141.31% | -356.82% | -540.49% | -153.77% | -213.38% | -186.5% | -140.48% | -132.68% | -69.46% | - | -31.65% | -74.61% | -72.29% | -51.06% | -90.7% |
| Income Tax | -1.88M | -1.75M | -271K | -271.09K | -368K | -484K | -298.19K | -298K | -305K | -198.54K | 2.77M | 1.44M | 955.1K | -339.62K | -9.11M | 1K | 10K | 1K | 4.18K | -1.18K | 1.35K | 2.62K | 117.28K | -7.42K | 44.41K | 58.79K | 21.77K | -1.05M |
| Effective Tax Rate % | 3.56% | 7.78% | 1% | 1.31% | 1.45% | 5.44% | 2.34% | 2.82% | 4.81% | 1.83% | -22.81% | -19.7% | -12.62% | 22.52% | 104.26% | -0.01% | -0.07% | -0% | -0.02% | 0% | -0.01% | -0.02% | - | 0.07% | -0.3% | -0.14% | -0.16% | 5.98% |
| Net Income | -50.68M | -20.7M | -26.78M | -20.47M | -25.01M | -8.42M | -12.47M | -10.27M | -6.04M | -10.67M | -12.06M | -7.14M | -7.47M | -1.03M | 1.31M | -6.5M | -12.35M | -18.93M | -20.25M | -20M | -16.23M | -12.23M | -12.5M | -10.41M | -14.66M | -42.65M | -13.68M | -17.08M |
| Net Margin % | -2008.78% | -49290.48% | -1160.23% | -3687419.82% | -250140% | -55.46% | -1261.75% | -656230.03% | -46071.1% | -121.42% | -296.29% | -8020.89% | -8583.13% | -96.58% | 53.43% | -320.89% | -124.6% | -169.8% | -152.55% | -115.53% | -120.15% | -69.47% | -76.49% | -31.63% | -74.83% | -72.39% | -51.14% | -88.37% |
| Net Income Growth % | -23.31% | 22.69% | -30.85% | 18.19% | -197.08% | 32.46% | -21.4% | -70.06% | 43.4% | 11.54% | -68.97% | 4.4% | -624.38% | -178.75% | 120.14% | 47.36% | 34.78% | 6.54% | -1.25% | -23.28% | -32.66% | 2.17% | -20.05% | 28.97% | 65.62% | -211.83% | 19.91% | - |
| Net Income (Continuing) | -50.98M | -20.7M | -26.78M | -20.47M | -25.01M | -8.42M | -12.47M | -10.27M | -6.04M | -10.67M | -12.15M | -7.31M | -7.57M | -1.51M | -1.47M | -5.34M | -15.81M | -23.79M | -20.25M | -20M | -16.23M | -11.48M | -11.28M | -10.41M | -14.66M | -42.65M | -13.68M | -17.08M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 148 | 0 | 0 | 0 | 0 | 0 | 0 | 4.04K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -303.84K | -98.74K | 0 | 1.64M | 191K | 1.99M | 5.09M | 4.94M | 4.06M | 2.14M | 3.72M | 3.01M | 568.42K | 765.54K | 0 | 0 | 0 |
| EPS (Diluted) | -16.24 | -18.90 | -55.00 | -55.00 | -95.00 | -35.80 | -80.00 | -85.60 | -59.80 | -109.30 | -135.20 | -143.45 | -226.25 | -42.70 | 64.15 | -302.15 | -574.05 | -883.50 | -985.45 | -973.60 | -792.65 | -599.80 | -617.75 | -542.45 | -767.80 | -2489.90 | -805.80 | -1498.00 |
| EPS Growth % | 61.7% | 65.64% | 0% | 42.11% | -165.36% | 55.25% | 6.54% | -43.14% | 45.29% | 19.16% | 5.75% | 36.6% | -429.86% | -166.56% | 121.23% | 47.37% | 35.03% | 10.35% | -1.22% | -22.83% | -32.15% | 2.91% | -13.88% | 29.35% | 69.16% | -209% | 46.21% | - |
| EPS (Basic) | - | -18.90 | -55.00 | -55.00 | -95.00 | -35.80 | -80.00 | -85.60 | -59.80 | -109.30 | -135.20 | -143.45 | -226.25 | -42.70 | 64.15 | -302.15 | -574.05 | -883.50 | -985.45 | -973.60 | -792.65 | -599.80 | -617.75 | -542.45 | -767.80 | -2489.90 | -805.80 | -1498.00 |
| Diluted Shares Outstanding | 3.12M | 1.1M | 479.6K | 368.6K | 265K | 235.4K | 152.46K | 120.01K | 100.96K | 97.63K | 89.2K | 49.76K | 33K | 24.15K | 21.57K | 21.5K | 21.5K | 21.42K | 20.55K | 20.55K | 20.47K | 20.39K | 20.24K | 19.2K | 19.1K | 17.13K | 16.97K | 11.4K |
| Basic Shares Outstanding | 3.12M | 1.1M | 479.6K | 368.6K | 265K | 235.4K | 152.46K | 120.01K | 100.96K | 97.63K | 89.2K | 49.76K | 33K | 24.15K | 21.57K | 21.5K | 21.5K | 21.42K | 20.55K | 20.55K | 20.47K | 20.39K | 20.24K | 19.2K | 19.1K | 17.13K | 16.97K | 11.4K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Imminent clinical funding shortfall
As indicated by the most recent financial statements, Kazia’s revenue has effectively evaporated, with the company reporting a 100% year-over-year decline in the latest quarter, underscoring its status as a pre-commercial entity entirely dependent on external capital rather than organic product sales to sustain operations.
The lack of consistent revenue streams suggests that the company remains in a pure developmental phase where financial performance is decoupled from commercial market activity. Investors should interpret the absence of top-line growth as a signal that the business model is currently optimized for intellectual property generation rather than revenue generation.
Based on reported figures, the company continues to incur significant R&D and SG&A expenses, with quarterly operating losses reaching $13.3 million in 2026Q2, highlighting a cost structure that remains disconnected from any meaningful revenue generation and places extreme pressure on the firm's limited cash reserves.
The persistent high level of R&D spending reflects the capital-intensive nature of late-stage clinical trials, yet the lack of corresponding commercial milestones suggests that these costs are currently unhedged. This expense discipline appears secondary to the necessity of maintaining clinical momentum, which may lead to further equity dilution.
According to historical income statement data, the company has failed to demonstrate operating leverage, as operating losses have consistently widened in periods of high R&D activity, confirming that the firm lacks the scale to offset its fixed administrative and research overhead through current operational activities.
The inability to scale operating income relative to gross profit suggests that the company's cost base is highly rigid and tied to clinical trial milestones rather than operational efficiency. This lack of leverage implies that any future path to profitability is entirely contingent on a successful clinical outcome or a strategic partnership.
As reported in financial filings, the company's cash position of $4.3 million against substantial quarterly operating losses suggests a precarious financial runway, raising significant concerns regarding the firm's ability to continue as a going concern without immediate and potentially dilutive capital market intervention in the near term.
Short-term observers may focus on the high probability of a capital raise, which could significantly impair existing shareholder value. The reliance on non-recurring income and the absence of a commercial product suggest that the current valuation may be overly optimistic regarding the company's ability to reach its next clinical milestone.
Quick answers to the most common questions about buying KZIA stock.
For fiscal year 2025, Kazia Therapeutics Limited (KZIA) reported total revenue of $0.0M. This represents a 99.8% decline compared to $19.3M in 1999.
Kazia Therapeutics Limited (KZIA) reported a net loss of $20.7M for the fiscal year ending 2025.
Kazia Therapeutics Limited (KZIA) reported an operating income of $-14.2M, resulting in an operating profit margin of -33850.0%. This margin reflects the operational efficiency of the business before interest and taxes.
Kazia Therapeutics Limited (KZIA) generated $0.0M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.